Table 2

Differences in proportions of patients with COPD treated with each therapy and total costs according to current clinical practice, NICE guidance [NG115] and GOLD 2020 strategy

TherapyHigh exacerbation history and current high symptomsHigh exacerbation history and current low symptomsLow exacerbation history and current high symptomsLow exacerbation history and current low symptoms
Current clinical practice
 LAMA, %0.470.604.268.97
 LABA, %0.020.090.390.93
 LAMA/LABA, %0.820.635.755.09
 LABA/ICS, %0.841.174.3310.03
 LAMA/LABA/ICS, %9.484.4323.5118.18
Treatment according to NICE guidance [NG115]
 LAMA, %0008.97
 LABA, %0000.93
 LAMA/LABA, %1.311.3230.3324.90
 LABA/ICS, %0.841.161.232.99
 LAMA/LABA/ICS, %9.484.436.675.42
Total savings vs current treatment£46.9 million (8%)
Treatment according to GOLD 2020 strategy
 LAMA, %0008.97
 LABA, %0007.97
 LAMA/LABA, %1.311.3230.3317.85
 LABA/ICS, %0.660.8702.99
 LAMA/LABA/ICS, %9.664.727.905.42
Total savings vs current treatment£43.7 million (8%)
  • COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled cortcosteroid; LABA, long-acting β2 agonist; LAMA, long-acting muscarinic antagonist; NICE, National Institute for Health and Care Excellence.